BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1473433)

  • 1. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin.
    Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
    Dig Dis Sci; 1992 Dec; 37(12):1847-52. PubMed ID: 1473433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
    Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
    Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism.
    Melarange R; Spangler R; Hoult JR
    Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):195-200. PubMed ID: 8931119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function.
    Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
    Br J Rheumatol; 1990 Apr; 29(2):116-9. PubMed ID: 2108782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.
    Melarange R; Gentry C; Durie M; O'Connell C; Blower PR
    Dig Dis Sci; 1994 Mar; 39(3):601-8. PubMed ID: 8131699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The unique pharmacologic profile of nabumetone.
    Blower PR
    J Rheumatol Suppl; 1992 Nov; 36():13-9. PubMed ID: 1474529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
    Jeremy JY; Thompson CS; Mikhailidis DP; Dandona P
    Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
    Soma LR; Uboh CE; Rudy JA; Smith MS
    Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions.
    Ishiwata Y; Okamoto M; Yokochi S; Hashimoto H; Nakamura T; Miyachi A; Naito Y; Yoshikawa T
    J Pharm Pharmacol; 2003 Feb; 55(2):229-37. PubMed ID: 12635655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function.
    Melarange R; Rashbrook LC
    J Pharm Pharmacol; 1987 Sep; 39(9):717-20. PubMed ID: 2445949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low direct cytotoxicity of nabumetone on gastric mucosal cells.
    Arai Y; Tanaka K; Ushijima H; Tomisato W; Tsutsumi S; Aburaya M; Hoshino T; Yokomizo K; Suzuki K; Katsu T; Tsuchiya T; Mizushima T
    Dig Dis Sci; 2005 Sep; 50(9):1641-6. PubMed ID: 16133963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration.
    Melarange R; Blower P; Spangler R
    Eur J Rheumatol Inflamm; 1994; 14(2):23-7. PubMed ID: 7744130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?
    Dandona P; Jeremy JY
    Drugs; 1990; 40 Suppl 5():16-24. PubMed ID: 2081487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA.
    Pillinger MH; Dinsell V; Apsel B; Tolani SN; Marjanovic N; Chan ES; Gomez P; Clancy R; Chang LF; Abramson SB
    Br J Pharmacol; 2004 Jul; 142(6):973-82. PubMed ID: 15210577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
    Melarange R; Gentry C; Blower PR; Toseland CD; Spangler R
    Eur J Rheumatol Inflamm; 1994; 14(2):15-22. PubMed ID: 7744129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the prodrug nabumetone, and its active metabolite, 6-MNA, on human and rat gastric mucosal prostanoids and platelet function.
    Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
    Drugs; 1990; 40 Suppl 5():53-6. PubMed ID: 2081494
    [No Abstract]   [Full Text] [Related]  

  • 17. Different effects of indomethacin and nabumetone on prostaglandin-mediated gastric responses to central vagal activation in rats.
    Cardin S; Soll AH; Taché Y
    J Pharmacol Exp Ther; 1995 Nov; 275(2):667-73. PubMed ID: 7473153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.
    Melarange R; Gentry C; O'Connell C; Blower PR
    Agents Actions Suppl; 1991; 32():33-7. PubMed ID: 2069095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies.
    Spangler RS
    Am J Med; 1993 Aug; 95(2A):35S-39S. PubMed ID: 8357001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers.
    Freed MI; Audet PR; Zariffa N; Krishna GG; Ilson BE; Everitt DE; Brown LE; Rizzo SM; Nichols AI; Jorkasky DK
    J Clin Pharmacol; 1994 Nov; 34(11):1098-108. PubMed ID: 7876402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.